Octagon Research Solutions Announces StartingPoint 4.0
Octagon Research Solutions, Inc., has released version 4.0 of its global submission document authoring template suite, StartingPoint.
StartingPoint 4.0 is designed to offer standardized templates and formatting functionality to those authoring the various components of a CTD (Common Technical Document) or eCTD (electronic Common Technical Document) regulatory submission. StartingPoint 4.0 offers new content templates, improved functionality and compliance with Windows 7.
New functionality includes:
* Enhanced error identification and management o
- Expanded list of errors highlighted by the Document Validation tool
- A new ‘Report Generation’ mode that enables the user to generate a comprehensive report of all errors found in the document.
- The addition of a ‘Replace All’ feature allowing replacement of all instances of erroneous style with one button push.
* Enhanced toolbar automation that addresses common challenges with table and footnote formatting
* Automated ‘Replace Styles’ functionality that allows the user to map each existing style in a document to a specified StartingPoint style.
* New and enhanced content templates reflecting recent changes in regulatory guidance including:
- 1.16 Proposed Risk Evaluation and Mitigation Strategies (REMS)
-1.16 Risk Evaluation and Mitigation Strategies (REMS) Supporting Document
-1.6.1 Meeting Request
-1.6.2 Pre-NDA Meeting Background Materials
“The Risk Evaluation and Mitigation Strategies (REMS) content template was added to this version of StartingPoint as a result of our agency interactions and is based on just released guidance from the FDA. We are seeing an increased emphasis on the REMS and felt it appropriate to include the content template to assist our clients in developing a framework for this critical document," stated John Lawrie, vice president, Process Consulting.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
